• DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi logo
  • DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Diseases
leishmaniasis icon

Cutaneous leishmaniasis

Symptoms, transmission, and current treatments for cutaneous leishmaniasis

Home > Diseases
leishmaniasis icon

Cutaneous leishmaniasis

Symptoms, transmission, and current treatments for cutaneous leishmaniasis

  • Overview
  • Facts
  • Projects & achievements
  • Target product profiles

What is cutaneous leishmaniasis? 

Cutaneous leishmaniasis is the most common form of leishmaniasis. It is caused by over 15 different species of the protozoan parasite Leishmania, transmitted by infected female sandflies.

Although cutaneous leishmaniasis is not life-threatening, it can have devastating effects on local communities. It causes disfiguring skin lesions that can leave life-long scars and lead to severe social stigma, especially for women and children. Consequences include ostracism, less education, and economic loss. These effects are especially severe since cutaneous leishmaniasis mostly affects people who already have only limited resources.

Mucocutaneous leishmaniasis can present as a complication of cutaneous leishmaniasis and can occur several months or even years after skin ulcers heal. Lesions can lead to partial or total destruction of the mucosal membranes of the nose, mouth, and throat cavities and surrounding tissues, resulting in social stigma and disability. Unlike most forms of cutaneous leishmaniasis, mucocutaneous leishmaniasis is unlikely to heal on its own; in cases of severe mucocutaneous leishmaniasis, people who do not receive treatment can die.

What is the impact of cutaneous leishmaniasis?

  • 600,000-1 million people infected every year
  • Endemic in 87 countries
  • In 2020 over 85% of new cutaneous leishmaniasis cases occurred in 10 countries: Afghanistan, Algeria, Brazil, Colombia, Iraq, Libya, Pakistan, Peru, the Syrian Arab Republic, and Tunisia
  • Effectiveness of current treatments can be as low as 50%
Cutaneous leishmaniasis epidemiology map

What are current treatments for cutaneous leishmaniasis?

Existing drugs have serious drawbacks in terms of safety, resistance, and availability. The drugs are not well tolerated, have to be taken for a long time, and are difficult to administer.

Pentavalent antimonials (sodium stibogluconate and meglumine antimoniate)

  • 21 days of painful intramuscular injections at a hospital or clinic
  • 1-2 applications to lesions per week for 3-7 weeks
  • Effectiveness in some regions can be as low as 50%
  • Toxic, with risk of serious cardiotoxicity leading to death
  • Less effective in children under five
  • Expensive
  • Daily hospital or clinic visits make it difficult for people to access treatment
  • Lengthy, arduous treatment has an economic impact on households, often causing caregivers of children with the disease and people from rural areas not to seek treatment or to discontinue treatment prematurely.

Miltefosine

  • 28-day, twice-a-day oral drug
  • Low adherence due to side effects and length of treatment
  • Cannot be used during pregnancy
  • Developing resistance
  • Not available in many countries
  • Cannot be used during pregnancy or without contraception among women who can have children

What new treatments for cutaneous leishmaniasis are needed?

Patients need a safe, topical or oral, well tolerated, and affordable treatment that can:

  • cure lesions quickly without leaving a deep scar, and
  • be deployed within clinics for self-treatment without requiring follow-up by health workers.

In complicated cases, the addition of immunomodulators could enhance the efficacy of antiparasitic drugs.

What cutaneous leishmaniasis treatments are we working on? 

We aim to make treatments safer, shorter and more affordable and effective. In the short term, better treatment regimens are being developed using existing treatments. In the long term, the goal is to develop an entirely new generation of all-oral drugs. We are focused on developing treatment for cutaneous leishmaniasis caused by L. tropica and L. braziliensis – because of the severity of these diseases and their impact.

Find out about our work developing treatments for cutaneous leishmaniasis

How do you get cutaneous leishmaniasis? 

  • Leishmania parasites are transmitted through the bites of infected female phlebotomine sandflies
  • Factors that influence people’s risk of infection include poor housing and domestic sanitary conditions; malnutrition; climate and environmental change; and migration

What are the symptoms of cutaneous leishmaniasis? 

Cutaneous leishmaniasis can present in different clinical forms, ranging from uncomplicated, self-healing skin lesions to debilitating, large, chronic or recurring lesions, disfiguring mucosal or muco-cutaneous lesions in the mouth or nose, or diffuse cutaneous leishmaniasis. Depending on the form and severity of the disease, cutaneous leishmaniasis can lead to severe social stigma and in some cases disability.

The sores typically progress from small bumps to open lesions with a raised border and central crater – or ulcer – which can be covered with scabs. The lesions usually are painless but can be painful, particularly if open sores become infected with bacteria.

How is cutaneous leishmaniasis diagnosed? 

A suspected case of cutaneous leishmaniasis is confirmed by testing for presence of the parasite in the lesion using a variety of techniques. A rapid diagnostic test is commercially available, but it is not widely used and does not perform satisfactorily in all cases.

More information 

  • WHO factsheet

Last updated: March 2022

Making medical history for neglected patients

We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them

Doctor diagnosing a man in a village with his hands on the man's neck

Sleeping sickness

Transmitted by the bite of a tsetse fly and causes severe neurological disorders

We delivered a revolutionary new drug to replace toxic treatments, and have ongoing trials to eliminate this disease

Young boy sitting on a hospital bed being examined by a nurse

Chagas disease

Causes heart and vital organ damage, after people are bitten by blood-sucking bugs

We delivered the first-ever treatment for children; now we’re searching for new drug candidates and working to boost access to care

Girl with skin lesions on her nose

Cutaneous leishmaniasis

Leaves disfiguring, life-long scars that lead to severe social stigma

We’re working to develop safer, shorter treatments for this disabling disease

Young man standing in the street

Hepatitis C

Millions are left without treatment even though effective drugs exist

We’ve delivered a treatment as simple, safe, and effective as the best drugs available today – at a fraction of the cost 

Girl looking over a fence

Visceral leishmaniasis

Is one of the world’s biggest parasitic killers, spread by the bites of sandflies

We’re working to develop a new generation of treatments to replace drugs that are painful, ineffective, and cause side effects

Healthcare workers in a hospital

COVID-19

Devasting and deadly to many, there’s too little research to help the most vulnerable

We’re accelerating research by coordinating clinical trials in low-resource settings and bringing together partners

Father walking in rural village with a cane and holding his son's hand

Filaria: river blindness

Lead to unbearable itching, disfiguring skin lesions, and even blindness

We’re working to develop a safe, effective, and affordable drug for the prevention and treatment of this debilitating disease

Patient medical examination

Cryptococcal meningitis

Without treatment, deadly for thousands of people with advanced HIV

We’re working to improve access to life-saving treatments and developing an easier-to-use formulation

Sleeping sickness

Chagas disease

Cutaneous leishmaniasis

Hepatitis C

Visceral leishmaniasis

COVID-19

Filaria: river blindness

Cryptococcal meningitis

VIEW ALL DISEASES

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

DNDi logo
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By continuing to browse our website, you are agreeing to our use of cookies.CLOSECOOKIE POLICY